Galenus Precision Pharmacy, Inc. — SEC Form D Filing

Galenus Precision Pharmacy, Inc. filed an SEC Form D on February 18, 2026, reporting $1.94M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
February 18, 2026
Amount reported
$1.94M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://galenuscare.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Adverse drug events lead to significant health issues and high costs in healthcare.

Solution

GalenusRx personalizes medication regimens and analyzes drug interactions to enhance safety and reduce costs.

Why now

There is a growing demand for personalized healthcare solutions to minimize adverse drug events.

Verdict

Investors said yes because Galenus Precision Pharmacy offered a timely solution to the pressing issue of adverse drug events, not because it presented a unique technological edge over competitors. They were implicitly betting on the increasing urgency for personalized healthcare solutions to mitigate risks in medication management while recognizing that the market is still prone to technology-related failures. The limited upside lies in a crowded field where similar innovations exist, suggesting that differentiators may not provide sustainable long-term value.

Source: SEC EDGAR Form D filing